Mirena (Levonorgestrel)

Levonorgestrel released from Mirena binds to progesterone receptors in the endometrium, causing glandular atrophy and reduced vascularity. It also thickens cervical mucus and suppresses the mid‑cycle luteinising hormone surge, which together prevent ovulation and create an environment hostile to sperm.

Mirena contains a total of 52 mg of levonorgestrel and releases the hormone at a low, continuous rate. The specific dosing regimen, including insertion timing and replacement interval, is determined by the prescribing clinician based on individual patient needs and regulatory guidelines.

Mirena is classified as pregnancy category X, meaning it must not be used by women who are pregnant or who may become pregnant. For breastfeeding women, the device can be used after delivery, but clinicians should assess risks and benefits, as levonorgestrel does pass into breast milk in low amounts.

To order Mirena, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral contraceptives, Mirena offers a once‑in‑five‑year dosing interval, higher contraceptive efficacy and reduced systemic hormone exposure. Unlike injectable progestins, it does not require clinic visits for repeat injections, and it provides the added benefit of reducing heavy menstrual bleeding, which many other methods do not address.

Mirena should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme heat. Do not attempt to open or manipulate the system before insertion by a qualified healthcare professional.

Mirena is inserted by a trained clinician into the uterine cavity through the cervical canal using a specialized inserter. The procedure is performed in a clinical setting under sterile conditions. Once placed, the device remains in situ for up to five years, after which it should be removed or replaced.

Serious risks include uterine perforation during insertion, device expulsion or displacement, and pelvic inflammatory disease or infection. Although rare, these complications require prompt medical attention. Patients should be educated on symptoms such as severe abdominal pain, abnormal bleeding or signs of infection.

Mirena is contraindicated in women who are pregnant, have known or suspected uterine malignancy, active pelvic infection, unexplained vaginal bleeding, or a history of uterine perforation. It should also be avoided in women with severe liver disease or those who are allergic to levonorgestrel or any component of the device.